Related Experiment Video
Updated: Sep 6, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial
Rama Bozorgmehr1, Farbod Amiri2, Mohammad Hosein Zadeh3
1Clinical Research Development Unit, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Introduction:
Efforts to control the COVID-19 pandemic are still on. This study aimed to evaluate the effect of sofosbuvir on length of hospital stay and complications in COVID-19 cases with moderate severity.
Methods:
This randomized clinical trial was done on moderate COVID-19 cases, who were admitted to Shohadaye Tajrish Hospital, Tehran, Iran, from 4/2021 to 9/2021. Eligible patients were randomly allocated into two groups of intervention (sofosbuvir) and control, and their outcomes were compared regarding the length of hospital stay and complications.
Results:
100 COVID-19 cases were randomly divided into two groups of 50 patients, as the intervention and control groups. The mean age of patients was 50.56 ± 12.23 and 57.1±14.1 years in the intervention and control groups, respectively (p = 0.02). The two groups were similar regarding distribution of gender (p = 0.15), underlying diseases (p = 0.08), the severity of COVID-19 (p = 0.80) at the time of admission, signs and symptoms (p > 0.05), and essential laboratory profile (p > 0.05). The length of hospital stay in the control and intervention groups was 7.7 ± 4.09 days and 4.7±1.6 days, respectively (p = 0.02). None of our patients needed ICU or mechanical ventilation.
Conclusion:
Sofosbuvir may decrease the length of hospital stay of COVID-19 cases with moderate severity, without a significant effect on the rate of intensive care unit (ICU) need and mortality.
Insights
Sofosbuvir treatment may reduce hospitalization duration for moderate COVID-19 patients. This antiviral did not significantly impact intensive care unit (ICU) admission or mortality rates in the study.
Area of Science:
- Infectious Diseases
- Virology
- Clinical Medicine
Background:
- The COVID-19 pandemic necessitates ongoing research into effective treatments.
- Moderate severity COVID-19 cases require interventions to manage hospital stay and prevent complications.
Purpose of the Study:
- To evaluate the efficacy of sofosbuvir in reducing hospital stay for moderate COVID-19 patients.
- To assess the impact of sofosbuvir on complications, including intensive care unit (ICU) admission and mortality.
Main Methods:
- A randomized clinical trial involving 100 moderate COVID-19 patients.
- Patients were allocated to either sofosbuvir intervention or control groups.
- Outcomes measured included length of hospital stay and complication rates.
Main Results:
- The sofosbuvir group had a significantly shorter mean hospital stay (4.7 days) compared to the control group (7.7 days).
- No significant difference was observed in the need for ICU admission or mechanical ventilation between groups.
- Patient demographics and baseline characteristics were comparable between the intervention and control groups.
Conclusions:
- Sofosbuvir shows potential in decreasing the length of hospital stay for moderate COVID-19.
- The study found no significant effect of sofosbuvir on ICU admission or mortality in this patient cohort.
More Related Videos
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Hospitals-II
Nurses that work in...
Retrovirus Life Cycles

